Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Industry association · Denmark
Industry association · Spain
Declared costs: €100K+ a year · in the register since 2015
Medicinal products for human use · Compulsory licensing of patents in crisis situations · Supplementary protection certificate for plant protection products. Recast
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Farmaindustria · filed 27 Apr 2021 · source
Farmaindustria considers it crucial to preserve the stability and predictability of the current European framework of incentives to attract investment and enable the pharmaceutical industry to continue to innovate in Europe, achieving better health outcomes.
Filed in Spanish · English published by the European Commission
Farmaindustria · filed 6 Nov 2023 · source
Farmaindustria (FI) supports the ultimate objective of the EC Proposal to improve the availability and access to medicines by promoting an innovative and competitive environment in the EU. We welcome the intention to prepare a regulatory framework for the future, maximising the use of fast-track procedures, optimising regulatory decision-making processes and reducing unnecessary red tape.
Filed in Spanish · English published by the European Commission
The Danish Association of the Pharmaceutical Industry · filed 7 Nov 2023 · source
On 26 April 2023, the European Commission published proposals for the reform of the EU pharmaceutical legislation revising existing legislation on medicines, with the aim of increasing the availability of medicines and vaccines, while at the same time strengthening scientific research and innovation in Europe for the benefit of patients.
Filed in Danish · English published by the European Commission
The Danish Association of the Pharmaceutical Industry · filed 29 Apr 2022 · source
Strong IP protection has allowed the pharmaceutical industry to react quickly to COVID-19 and facilitates the cooperation and partnerships needed to defeat the virus and end the pandemic. Much of this work builds on products, knowledge and research capacities developed over many years to support a strong and stable IP system.
Filed in Danish · English published by the European Commission
Farmaindustria · filed 28 Jul 2023 · source
The EC proposal on the granting of compulsory licences (LO) is of great concern to FARMAINDUSTRIA by providing for the suspension of IP rights and preventing the choice of partners to voluntarily grant manufacturing licences for their products without any legal basis being observed to limit the use of this measure.
Filed in Spanish · English published by the European Commission
The Danish Association of the Pharmaceutical Industry · filed 31 Jul 2023 · source
This proposal is extremely worrying, especially as patents enabled the pharmaceutical industry to react quickly to COVID-19 and laid the foundations for the cooperation and partnerships needed to defeat the virus and end the pandemic. Much of this work was based on products, knowledge and research capacities developed over many years, supporting a strong and stable IP system.
Filed in Danish · English published by the European Commission
Farmaindustria · filed 26 Mar 2022 · source
Making new therapies available to patients is a long, complex and risky process that requires considerable investment, giving industrial protection — and the period for which it is effective — a key role in embarking on this process.
Filed in Spanish · English published by the European Commission
The Danish Association of the Pharmaceutical Industry · filed 4 Apr 2022 · source
Research and development of new innovative medicines is a very costly and lengthy process, thus also entailing significant commercial risks for businesses. Patents are therefore a prerequisite for a successful pharmaceutical industry that creates value and welfare for patients.
Filed in Danish · English published by the European Commission
The Danish Association of the Pharmaceutical Industry · filed 4 Apr 2022 · source
Research and development of new innovative medicines is a very costly and lengthy process, patents are therefore a prerequisite for a successful pharmaceutical industry that creates value and welfare for patients. SPCs, ensure sustainable financing of innovation by precisely compensating for the period of patent exclusivity lost during a lengthy and costly research and development process.
Filed in Danish · English published by the European Commission
Farmaindustria · filed 18 Sept 2023 · source
Farmaindustria, as the representative of the innovative pharmaceutical industry established in Spain, welcomes the proposed revision of the SPC Regulation of, given its objective of creating a harmonised and centralised approach to the application, evaluation and granting of SPC for both classical European and unitary patents (UPs), providing a clearer and more efficient framework for industrial property in the EU…
Filed in Spanish · English published by the European Commission
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.